Low Testosterone in Women Symptoms: What the Evidence Actually Supports

The low testosterone symptom list you've been reading

Low testosterone in women symptoms as described across the internet: low sex drive, fatigue, brain fog, low mood, muscle weakness, weight gain, and thinning hair. The list appears on clinic websites, consumer articles, and supplement pages with consistent confidence. Here's the problem: the confidence is not coming from the evidence.

The 2019 Global Consensus Position Statement — endorsed by 11 international societies, based on a systematic review of the randomized trial data — addresses most of these symptoms directly. Its conclusions are not what most of the marketing implies.

And the 2025 AMY Study — the largest, most rigorous measurement of female testosterone across the menopause transition, using mass spectrometry in 1,104 women — found no testosterone drop at natural menopause. That finding removes the biological premise the symptom list is usually built on.

Evidence table: what testosterone actually treats in women

Every row below is graded from the trial data. "Not directly studied" is not the same as "disproven" — but it means no RCT has targeted that symptom, and "I felt better" is not the same as a controlled effect.

Sources: Davis SR, et al. Global Consensus Position Statement. J Clin Endocrinol Metab. 2019;104(10):4660-4666. Islam RM, et al. Safety and efficacy of testosterone for women. Lancet Diabetes Endocrinol. 2019;7(10):754-766. 2026 IMS Recommendations, International Menopause Society.

The honest size of the win for HSDD

For postmenopausal women with HSDD, the evidence is real — but it's worth knowing what the magnitude looks like. A 2019 meta-analysis of 36 randomized trials found testosterone produced approximately 0.85 more satisfying sexual events per month compared to placebo. That's a real, statistically significant effect. It's also not a dramatic transformation for every woman who tries it.

The consensus is also candid: endogenous testosterone levels do not reliably predict who will respond. A low result doesn't mean testosterone will help you, and a result inside the reference interval doesn't mean it won't. The decision is clinical, not numerical.

The 2025 AMY Study: the data that moved the needle

The AMY Study (Australian Women's Midlife Years Study) published in 2025 is the largest, most rigorous cross-sectional measurement of female testosterone across midlife that exists. Key features: 1,104 women aged 40-65, mass spectrometry (LC-MS/MS), not a standard immunoassay.

Its three most important findings:

If it's not testosterone, what is it?

Three separate studies from 2025 converge on the same point, using three different methods. The Lancet Diabetes & Endocrinology cross-sectional symptom data from the AMY Study showed which symptoms actually cluster with menopause. The eBioMedicine testosterone paper showed which hormone changes actually occur. The Global Consensus meta-analysis showed which symptoms testosterone actually treats. Put all three together and the picture is coherent: most of the symptom list belongs to a different conversation.

These are evaluation categories, not diagnoses, and not a test panel to demand. Which ones are relevant depends on your history, your medications, your bleeding pattern, your surgical history, and what's actually bothering you most.

Why estrogen is often the better conversation

On November 10, 2025, the FDA requested labeling changes for menopausal hormone therapies. On February 12, 2026, the FDA approved revised labeling for six of those products — removing boxed-warning language about cardiovascular disease, breast cancer, and probable dementia. Those actions covered estrogen and estrogen/progestogen products.

What a clinician might check first

Depending on your history, a clinician may consider looking at:

• Thyroid function
• Ferritin and CBC — iron deficiency is common in perimenopause when bleeding can get heavy, and it can produce fatigue, brain fog, and hair loss all at once
• Sleep — including screening for sleep apnea
• Mood
• Your current medications
• Whether your hot flashes and vaginal symptoms are actually being treated

None of that is required for every reader, and a clean result on all of it doesn't automatically mean testosterone is the answer. But if you've been told "your labs are normal" and nobody checked your ferritin, that's a fair thing to ask about.

What actually lowers testosterone in women

The main causes are age, having both ovaries removed, and medication effects — including the one almost nobody mentions: oral estrogen raises SHBG, a protein that binds testosterone and changes how your results read. Natural menopause has not been shown to lower testosterone.

SHBG is sex hormone-binding globulin — a protein in your blood that binds a large share of your testosterone. Bound testosterone is still circulating; it just isn't free. When something raises your SHBG, the balance between total and free testosterone shifts, and that changes how your lab result should be read.

Sources: Zimmerman Y, et al. Hum Reprod Update. 2014;20(1):76-105. The Menopause Society, 2022. Wang Y, et al. eBioMedicine. 2025;121:105972.

Hysterectomy and ovary removal are not the same thing

This trips up an enormous number of women, and the internet is not helping.

You can have a hysterectomy and keep both ovaries. You can have a hysterectomy with a bilateral oophorectomy at the same time. The AMY Study excluded women who'd had both ovaries removed from its main analysis for exactly this reason, then analysed them separately, where the testosterone difference showed up clearly.

If your symptoms started after surgery, get your operative report before your appointment. Not what you remember being told. The document. "I had a hysterectomy" and "I had both ovaries removed" are two different medical situations with two different hormone conversations.

Other conditions that can alter the picture

• Premature ovarian insufficiency — ovaries stopping early
• Adrenal insufficiency — your adrenal glands make androgen precursors too
• Hypopituitarism — a pituitary problem changes the whole picture
• Anti-androgen medications — spironolactone and finasteride, among others, can alter how androgens act or are metabolized

Those aren't self-diagnosis material. They're reasons to see a clinician in person rather than start a subscription.

Should I get my testosterone tested?

A testosterone result cannot diagnose HSDD or prove that fatigue, brain fog, weight change, or low mood are caused by testosterone. No blood level designates female testosterone deficiency, and most routine immunoassays lack precision at the concentrations found in women. Testing is genuinely useful for three narrower things: documenting a baseline before treatment, spotting an unexpectedly high value, and monitoring treatment so levels don't run too high.

What a "low" result actually means

It means the value your sample produced was below the reference interval for that lab's assay. That's it. That's the whole claim.

It does not mean testosterone is causing your symptoms. It doesn't mean you have a deficiency syndrome. And it doesn't predict whether testosterone would help you — endogenous testosterone levels don't reliably predict who responds.

Bring the whole report to your appointment: result, units, reference interval, date, method, whether it's total or free, SHBG if measured, and why the test was ordered. The number without that context isn't much of a number.

So why does any good provider test at all?

Because a testosterone measurement has two real jobs:

1. Documenting a baseline before treatment — including catching an unexpectedly high starting value. Midi, for example, lists testosterone above 100 ng/dL as a reason not to prescribe.
2. Monitoring during treatment, so you don't drift into supraphysiologic levels. The consensus recommends a baseline before starting, a recheck at 3-6 weeks, then periodically.

Notice what's not on that list: ruling out thyroid disease, iron deficiency, or sleep apnea. The testosterone result doesn't do that. Your history, your examination, and separate targeted tests do.

A clinic should not use a testosterone cutoff by itself to diagnose HSDD or decide whether you're eligible — because no such validated cutoff exists. Baseline testing as one part of a broader clinical assessment is completely appropriate. A number used as a gate is not.

Are at-home testosterone tests good enough?

Not for deciding whether you have "low T" — and not for the reason you'd expect. The collection isn't really the issue. The issue is everything around it: which assay ran it, what reference interval it's being compared against, and what decision the result would actually change.

The real risk isn't a wrong number. It's a right number, misread. You get a result flagged "low," it finally feels like an explanation, and you spend the next year treating the wrong thing while your ferritin sits at 8 and nobody's looked.

Who is testosterone for women actually right for?

Testosterone has clear evidence for a specific woman: postmenopausal, with sexual desire that is persistently low and genuinely distressing, where a proper assessment has considered the other contributors — pain, GSM, medications, mood, sleep, and relationship factors. If that's you, the evidence is real and you deserve access to it. If it isn't, it isn't.

What is HSDD — and how is it actually diagnosed?

HSDD is hypoactive sexual desire disorder: sexual desire that's persistently or repeatedly low, causes you marked distress or difficulty in your relationship, and isn't better explained by another medical or psychiatric condition, a relationship problem, a medication, or another substance.

Three things follow from that definition, and they're the three things clinics gloss over:

1. The distress is part of the diagnosis. If your desire is lower and you're at peace with it, that isn't HSDD. That's a life change, and it doesn't need a prescription.
2. The exclusion step is part of the diagnosis. "Not better explained by something else" is doing real work. If sex hurts, or you're on an SSRI, or you haven't slept properly in two years — that has to be addressed as part of the assessment, not waved past.
3. No blood test makes this diagnosis. It's clinical. A number can't confirm it and a number can't rule it out.

You're likely a fit if

• ✅ You're postmenopausal — natural or surgical — and
• ✅ Your sexual desire is persistently low and it distresses you — and
• ✅ The other contributors — pain, GSM, vasomotor symptoms, sleep, medications, mood, relationship factors — have been assessed and addressed where they're relevant

You're likely not a fit if

We're going to tell you to leave. Most pages won't. Here's who should:

• ❌ You're premenopausal. The 2026 IMS Recommendations find insufficient evidence to support routine testosterone prescribing for premenopausal HSDD. Perimenopause symptoms checklist →
• ❌ Your main complaint is fatigue, brain fog, weight, or mood. Trials found no significant benefit for these outcomes. Mood and cognition → · Sleep →
• ❌ Sex hurts. GSM is a common cause. Testosterone is not an established routine treatment for GSM. Vaginal estrogen is FDA-approved for it. Vaginal estrogen and GSM →
• ❌ You want it for bone or muscle. No effect on bone density at 12 months. No significant benefit for lean mass or strength. HRT benefits and risks →
• ❌ You have a history of hormone-sensitive breast cancer. Women with prior breast cancer were excluded from the trials. The safety findings don't cover you. See a clinician in person.
• ❌ You're at high cardiometabolic risk. Also excluded from the trials.

Is there an FDA-approved testosterone for women?

No. There has never been an FDA-approved testosterone product for women in the United States. Every woman using testosterone in the US is using either a product approved for men, prescribed off-label at a much lower dose, or a compounded preparation. A women-specific testosterone formulation is approved in Australia, the United Kingdom, New Zealand, and South Africa — but not in the US.

The timeline nobody puts in one place

Testosterone is a Schedule III controlled substance

Testosterone is a Schedule III controlled substance in the United States. It requires a valid prescription from a licensed clinician. Under federal law, an authorized Schedule III prescription may be refilled up to five times within six months. Current federal telemedicine flexibilities remain in effect through December 31, 2026.

If a website offers you testosterone without a prescription, or without a genuine clinical evaluation, stop there. That's not a shortcut. That's a different category of problem.

Compounded is not FDA-approved. Ever.

Not "less rigorously." Doesn't. A compounded testosterone cream has not been through FDA premarket review. The FDA has specifically flagged describing compounded preparations as FDA-approved or as "clinically proven" as misleading in its guidance to telehealth companies.

And here's the genuine tension: the Global Consensus recommends against compounded testosterone — and acknowledges that where no approved female product exists, a compounded product may be needed, in which case the compounding pharmacy should meet Good Manufacturing Practice standards. In the US, both halves of that sentence apply at once. That's not a loophole. It's an unresolved regulatory gap.

Pellets: the one thing the consensus is unambiguous about

The Global Consensus recommends against any preparation that produces supraphysiologic testosterone concentrations — specifically including pellets and injections — and states that its efficacy findings do not apply to them.

Pellets are implanted under the skin. The dose can't be adjusted after insertion. Removal may require another procedure and may not reverse your exposure quickly. If a clinic leads with pellets, that tells you what you need to know about the clinic.

Are there FDA-approved treatments for low desire that aren't testosterone?

Yes — two. This is a fact that deserves to be on the page:

"Acquired" means the low desire is a change from how you used to be. "Generalized" means it isn't limited to one partner or one situation. We're not recommending either — each has its own contraindications and side-effect profile, and those conversations belong with a clinician who knows your history. What we're telling you is that the menu is bigger than the one you've been shown.

What are the risks and side effects of testosterone for women?

In randomized trials of selected, generally lower-risk postmenopausal women taking physiologic doses over limited follow-up, testosterone did not increase serious adverse events. The realistic side effects are mild acne and increased body or facial hair. The bigger issues are what the data doesn't cover: women at high cardiometabolic risk were excluded, and randomized safety evidence beyond 24 months is not established.

The stop rule

Current IMS guidance: benefits generally begin to emerge after four to six weeks, and if there's no significant benefit by six months, stop. Not increase the dose. Stop.

The treatment plan should define the target outcome and the reassessment schedule at the start. A provider who can't tell you what they're measuring and when they'll decide isn't following the guidance. That's a first-visit question, not a fifth-visit question.

Which online providers actually prescribe testosterone to women?

Fewer than you'd think. Of the major women's telehealth platforms, Midi Health publishes a testosterone program using a compounded cream, requiring lab work and typically two visits before a prescription. Winona states it does not prescribe testosterone. Hers does not list testosterone on its current perimenopause treatment page. All verified July 15, 2026.

Excluded from this comparison: Sesame and Inner Balance (Oestra). We could not verify their testosterone prescribing policies as of July 15, 2026, so we're not publishing rows for them. An empty row and a verified row shouldn't look alike.

The audit: where provider claims outrun the evidence

Midi and Winona are both HRT Index affiliate partners. We publish this anyway. If we didn't, nothing else on this page would be worth much.

Where this evidence is contested

Not everyone accepts the reading on this page. A minority of clinicians and researchers argue the trials were too short, measured the wrong things, and applied a standard of evidence to women that was never applied to men. That argument deserves a fair hearing, so here it is — made as well as we can make it, not as a straw man.

The case for a more permissive view

The double standard is real, and it's hard to wave away. There are many FDA-approved testosterone products for men and none with a female indication. Critics — including researchers who worked on the female testosterone trials themselves — have argued this reflects how seriously men's and women's sexual health are taken, not a difference in the evidence.

The trials may have measured the wrong thing. The consensus itself recommends that "satisfying sexual events" should no longer be used as the primary measure, and notes that no existing questionnaire captures every domain of female sexual function. If the yardstick is wrong, "no significant benefit" findings are weaker than they look.

"Insufficient" is not "it doesn't work." For premenopausal women and for cognition, the evidence is too limited to build a recommendation on — not the same as a finding of no effect.

If a provider tells you testosterone is fine premenopausally, they may be leaning on ISSWSH. That's a defensible position to argue, but it isn't the current IMS position, and you're entitled to know there's a disagreement rather than be told it's settled.

One disclosure we think you should have

Susan Davis — lead author of the Global Consensus Position Statement and senior author of the 2025 AMY Study — discloses that she has served on advisory boards for Besins Healthcare and has received institutional research funding and trial drug supply from Lawley Pharmaceuticals, which makes a testosterone product for women.

A disclosed financial relationship is neither evidence for nor against a study's findings. It's a potential conflict you're entitled to know about, and it's a reason to look at the methods — not a reason to dismiss the work. We're flagging it because nobody else on the first page of results did.

How we researched and verified this page

This page is editorial research. It is not medical advice, and it has not been reviewed by a clinician. Medical and regulatory claims are traced to current guidelines, FDA materials, prescribing information, or peer-reviewed research. Provider claims are labeled separately as provider-stated commercial facts and dated to the page we read. Editorial conclusions are labeled as ours.

We separate three kinds of statement:

• Medical or regulatory fact — sourced to primary or authoritative material. Never to a competitor's blog.
• Verified commercial fact — read on the provider's own live page, with the date we read it.
• Editorial conclusion — our judgment, based on the facts above, labeled so you can disagree with it.

What we didn't do: We didn't enroll. We didn't order. We haven't tested any product. We can't tell you how any provider's published process performs in real life, and you should be suspicious of any affiliate site that claims otherwise. Full methodology →

Frequently asked questions

So where does this leave you?

You now have the evidence distinctions and the questions you need for a much more focused conversation with a clinician. The honest summary:

• → If your desire is persistently low, you're postmenopausal, and it genuinely distresses you — testosterone is a real, evidence-backed option for clinically assessed HSDD. Ask about Addyi too.
• → If your main complaints are fatigue, brain fog, weight, or mood — those symptoms don't establish testosterone deficiency. Your next evaluation may need to look at sleep, thyroid, iron, medications, mood, and menopause symptoms.
• → If you're on oral menopausal estrogen — ask whether route and SHBG are relevant before you buy anything.
• → If your symptoms started after surgery — get the operative report. "Hysterectomy" and "both ovaries removed" are not the same thing.
• → If you're premenopausal — the guidelines disagree with each other. Know that going in.

Sources

1. 2026 IMS Recommendations, International Menopause Society.
2. Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019;104(10):4660-4666. Endorsed by 11 international societies.
3. Wang Y, Islam RM, Bond M, Davis SR. Testosterone and pre-androgens by age and menopausal stage at midlife: findings from a cross-sectional study. eBioMedicine. 2025;121:105972. doi:10.1016/j.ebiom.2025.105972. (Open access, CC BY.)
4. Islam RM, Bond M, Ghalebeigi A, Wang Y, Walker-Bone K, Davis SR. Symptom prevalence across the menopause transition. Lancet Diabetes Endocrinol. 2025;13(9):765-776.
5. Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019;7(10):754-766.
6. Parish SJ, Simon JA, Davis SR, et al. ISSWSH Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. J Sex Med. 2021;18(5):849-867.
7. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794.
8. Zimmerman Y, Eijkemans MJC, Coelingh Bennink HJT, et al. The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta-analysis. Hum Reprod Update. 2014;20(1):76-105.
9. Handelsman DJ, Davis SR. Measuring serum testosterone in women. Lancet Diabetes Endocrinol. 2024;12(7):437-439.
10. US Food and Drug Administration — labeling change request for menopausal hormone therapies (November 10, 2025); approved revised labeling for six MHT products (February 12, 2026).
11. US Food and Drug Administration — class-wide labeling changes for testosterone products (2025).
12. US Food and Drug Administration — human drug compounding; and FDA & Telehealth Companies: What to Know When Promoting Compounded Drugs (June 2026).
13. US Food and Drug Administration — prescribing information, Addyi (flibanserin) and Vyleesi (bremelanotide).
14. US Drug Enforcement Administration — controlled substance schedules and refill requirements.
15. Midi Health — testosterone program page, store page, Custom Rx page, and blog. Read July 15, 2026.
16. Winona — HRT FAQ and DHEA product page. Read July 15, 2026.
17. Hers — perimenopause treatment page. Read July 15, 2026.

The HRT Index is the independent menopause HRT decision layer for women. This page is editorial research, not medical advice, and has not been reviewed by a clinician. We have active affiliate relationships with Hers, Midi Health, Winona, and Sesame; this page contains one compensated link, to Midi Health. Last verified July 2026.